These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 9314610

  • 21. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
    Huitema AD, Spaander M, Mathĵt RA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S.
    Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
    [Abstract] [Full Text] [Related]

  • 22. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
    Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E.
    J Clin Oncol; 1992 Apr; 10(4):520-8. PubMed ID: 1548516
    [Abstract] [Full Text] [Related]

  • 23. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
    Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM.
    J Clin Oncol; 2000 Nov 01; 18(21):3677-89. PubMed ID: 11054441
    [Abstract] [Full Text] [Related]

  • 26. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF, Willemse PH, Sleijfer DT, Uges DR, Postmus PE, Meijer S, Terheggen PM, Mulder NH, de Vries EG.
    J Clin Oncol; 1991 Jan 01; 9(1):100-10. PubMed ID: 1985158
    [Abstract] [Full Text] [Related]

  • 27. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Duffaud F, Digue L, Tranchand B, Monjanel-Mouterde S, Guillet P, Nicoara A, Baciuchka M, Bagarry-Liegey D, Lacarelle B, Noble A, Durand A, Favre R.
    Ther Drug Monit; 2006 Apr 01; 28(2):212-8. PubMed ID: 16628133
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R, Kaneuchi M, Nishiya M, Todo Y, Takeda M, Okamoto K, Negishi H, Sakuragi N, Fujimoto S, Hirano T.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):137-42. PubMed ID: 12172979
    [Abstract] [Full Text] [Related]

  • 31. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.
    Thomas H, Boddy AV, English MW, Hobson R, Imeson J, Lewis I, Morland B, Pearson AD, Pinkerton R, Price L, Stevens M, Newell DR.
    J Clin Oncol; 2000 Nov 01; 18(21):3614-21. PubMed ID: 11054434
    [Abstract] [Full Text] [Related]

  • 34. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant.
    Colby C, Koziol S, McAfee SL, Yeap B, Spitzer TR.
    Bone Marrow Transplant; 2002 Mar 01; 29(6):467-72. PubMed ID: 11960264
    [Abstract] [Full Text] [Related]

  • 35. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ, Hudes GR, Walczak J, Schilder R, LaCreta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA.
    Cancer Res; 1992 Dec 15; 52(24):6746-53. PubMed ID: 1458462
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
    Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE, Pizzorno G.
    J Clin Oncol; 1997 May 15; 15(5):1945-52. PubMed ID: 9164206
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Lopez AM, Ketchum M, Nichols H, Xu MJ, Peng YM, Dorr R, Alberts DS.
    Cancer Chemother Pharmacol; 2000 May 15; 46(5):411-5. PubMed ID: 11127946
    [Abstract] [Full Text] [Related]

  • 39. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.
    Cancer Invest; 2005 May 15; 23(6):511-9. PubMed ID: 16203659
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.